Fig. 1From: A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)Schematic of Study Design. *Registration should take place no later than 2Â weeks after the beginning of screeningBack to article page